Chronic-dose Safety and Efficacy Study of a Bronchodilator Inhaler in Pediatric Asthmatics
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the repeat-dose safety and effectiveness of a
bronchodilator inhaler relative to placebo (inactive drug inhaler) in children aged 4-11
years with asthma. The dosing period lasts three weeks and starts following a three-week
run-in period.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.